



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ursocholic acid-d₄

Cat. No.:	HY-113212S
Molecular Formula:	C ₂₄ H ₃₆ D ₄ O ₅
Molecular Weight:	412.6
Target:	Isotope-Labeled Compounds; Apoptosis; Endogenous Metabolite
Pathway:	Others; Apoptosis; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Ursocholic acid-d₄ is deuterium labeled Ursocholic acid. Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis^{[1][2][3][4][5][6]}.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Ikegami, et al. Ursodeoxycholic acid: mechanism of action and novel clinical applications. *Hepatology Research* 38.2 (2008): 123-131.
- [3]. MacDonald IA, et al. Formation of ursodeoxycholic acid from chenodeoxycholic acid by a 7 beta-hydroxysteroid dehydrogenase-elaborating *Eubacterium aerofaciens* strain cocultured with 7 alpha-hydroxysteroid dehydrogenase-elaborating organisms. *Appl Environ Microbiol*. 1982 Nov;44(5):1187-95.
- [4]. Kim, et al. Ursodeoxycholic acid attenuates 5-fluorouracil-induced mucositis in a rat model. *Oncology letters* 16.2 (2018): 2585-2590.
- [5]. Lee HI, et al. Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin. *Int J Clin Pharmacol Ther*. 2014 Nov;52(11):981-5.
- [6]. Dubreuil, et al. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. *Liver international* 33.7 (2013): 1029-1038.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA